Clinical Trials Logo

Huntington Disease clinical trials

View clinical trials related to Huntington Disease.

Filter by:

NCT ID: NCT05707663 Recruiting - Clinical trials for Juvenile-Onset Huntington Disease

Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's Disease

Start date: April 17, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about brain development in Juvenile-onset Huntington's Disease (JoHD). The main questions it aims to answer are: - Is brain development different in JoHD than Adult-onset Huntington's Disease (AoHD)? - Can reliable biomarkers for JoHD be found in brain structure and function? Participants will be asked to complete cognitive tests, behavioral assessments, physical and neurologic evaluation, and MRI. Data collected will be compared to populations who are at-risk for HD and who have been diagnosed with HD as adults.

NCT ID: NCT05686551 Recruiting - Huntington Disease Clinical Trials

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

Start date: February 3, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease.

NCT ID: NCT05668520 Enrolling by invitation - Huntington Disease Clinical Trials

A Pilot Study of Nutritional Status in Patients With Huntington's Disease

Start date: October 1, 2022
Phase:
Study type: Observational

It is known that weight loss is a poor prognostic marker in HD, but it is not known which dietary interventions are optimal at different stages of the disease. Current guidelines for HD treatment are informed only by studies in people with other causes of weight loss. Our long term goal is to create the evidence base for improved nutritional management in HD. This study will pilot the tools to inform the development of clinical trials protocols. We want to know which measures can be used by patients manifesting obvious clinical features of HD, and which are most helpful in detecting clinically meaningful changes in nutrition status.

NCT ID: NCT05655520 Recruiting - Huntington Disease Clinical Trials

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Start date: December 14, 2022
Phase: Phase 3
Study type: Interventional

The primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)

NCT ID: NCT05541627 Active, not recruiting - Huntington Disease Clinical Trials

A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

Start date: October 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II Dose-Finding Study to Evaluate Striatal Administration of AB-1001 (previously BV-101) in Adults with Early Manifest Huntington's Disease

NCT ID: NCT05534139 Recruiting - Huntington Disease Clinical Trials

Clinicopathological MRI and CSF Correlates in Huntington's Disease.

Start date: August 11, 2021
Phase:
Study type: Observational

In this study the investigators will link brain iron levels obtained from quantitative susceptibility maps of HD patients with specific and well-known clinical CSF markers for iron accumulation, neurodegeneration and neuroinflammation. The relationship between iron accumulation and neuroinflammation, and the clinical and genetic characteristics of HD will be investigated. This will provide an important basis for the evaluation of brain iron levels as an imaging biomarker for disease state in HD and their relationship with the salient pathomechanisms of the disease.

NCT ID: NCT05509153 Not yet recruiting - Huntington Disease Clinical Trials

A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers

NAC-preHD
Start date: November 1, 2022
Phase: Phase 2
Study type: Interventional

NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.

NCT ID: NCT05475483 Active, not recruiting - Huntington Chorea Clinical Trials

Efficacy and Safety on SOM3355 in Huntington's Disease Chorea

Start date: August 2, 2022
Phase: Phase 2
Study type: Interventional

Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic movements.

NCT ID: NCT05360082 Not yet recruiting - Huntington Disease Clinical Trials

Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.

Start date: September 2024
Phase:
Study type: Observational

Positron Emission Tomography (PET) is a functional imaging technique, which enables in vivo visualization of biological molecules expressed in human tissues. Brain PET is most powerful to study a vast range of neurological and psychiatric disorders in vivo, targeting neuronal and glial activity, metabolism, cerebral blood flow, receptor proteins or misfolded proteins. In vivo imaging of synaptic density in the human brain has become feasible through development of [11C]UCB-J, a PET radioligand for the synaptic vesicle protein SV2A, which is ubiquitously and homogeneously present in presynaptic terminals throughout the brain. A first study in Huntington's disease (HD) mutation carriers showed loss of striatal [11C]UCB-J binding (also when corrected for atrophy), as well as in the neocortex (Delva et al, Neurology 2022). Moreover, regional synaptic loss was highly correlated to motor impairment. In order to be able to use SV2A PET as widespread available biomarker tool to assess synaptic integrity, disease progression and/or response to mHTT lowering drugs, the short half-life of 11C (20 minutes) for [11C]UCB-J remains a hurdle. Recently, [18F]SynVesT-1, an optimized 18F-labeled analogue of [11C]UCB-J with similar kinetics, binding affinity, and test-retest precision properties has been evaluated in humans. However, there is evidence from preclinical studies conducted at University of Antwerp that in the zQ175DN knock-in mouse model of HD, larger variability and lower effect-sizes are seen with [18F]SynVest-1 than with [11C]UCB-J. In order to ascertain a similar effect size and quantification properties for [18F]SynVest-1 and [11C]UCB-J PET in human HD, both in the premanifest and manifest phase, and to validate simplified measures (such as SUVR with white matter as reference region) and SynVest, this head-to-head fully quantitative study is performed.

NCT ID: NCT05358821 Completed - Huntington Disease Clinical Trials

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Start date: June 22, 2022
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.